← Eichor
Study identifier: NCT03910569 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study

Condition: Takotsubo Cardiomyopathy  ·  Sponsor: Cedars-Sinai Medical Center

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.

This description comes directly from the study's public registry record.

Talk to the study team

TS Registry  ·  310-248-8563  ·  takotsuboresearch@cshs.org

BS WHC, MS  ·  310-423-9666  ·  bswhc.research@cshs.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cedars Sinai Medical CenterLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03910569